×
Newsmax TV & Webwww.newsmax.comFREE - In Google Play
VIEW
×
Newsmax TV & Webwww.newsmax.comFREE - On the App Store
VIEW
Skip to main content
Tags: Lilly | Drop | Profit | drug

Lilly Projects Sharp Drop in 2012 Profit

Thursday, 05 January 2012 08:26 AM EST

Eli Lilly & Co. forecast a steeper-than-expected decline in profit for 2012, the first full year without exclusive rights to its big-selling Zyprexa schizophrenia treatment.

Shares fell 3.5 percent after Lilly announced its forecast on Thursday.

The drugmaker projected earnings in the range of $3.10 per share to $3.20 per share for 2012. For 2011, Lilly said it expects to meet or exceed its profit forecast of $4.30 per share to $4.35 per share, excluding items. Including items, Lilly sees 2011 earnings per share of $3.84 to $3.89.

Analysts were looking for $3.61 per share in 2012, according to Thomson Reuters I/B/E/S.

Zyprexa, a $4.5 billion-a-year product, began facing competition in October from low-cost generic versions in the United States.

© 2023 Thomson/Reuters. All rights reserved.


120
2012-26-05
Thursday, 05 January 2012 08:26 AM
Newsmax Media, Inc.

Sign up for Newsmax’s Daily Newsletter

Receive breaking news and original analysis - sent right to your inbox.

(Optional for Local News)
Privacy: We never share your email address.
Join the Newsmax Community
Read and Post Comments
Please review Community Guidelines before posting a comment.
 
TOP

Newsmax, Moneynews, Newsmax Health, and Independent. American. are registered trademarks of Newsmax Media, Inc. Newsmax TV, and Newsmax World are trademarks of Newsmax Media, Inc.

NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved
Download the NewsmaxTV App
Get the NewsmaxTV App for iOS Get the NewsmaxTV App for Android Scan QR code to get the NewsmaxTV App
NEWSMAX.COM
America's News Page
© Newsmax Media, Inc.
All Rights Reserved